Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06599619 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Effects of Anti-PD1 Adjuvant Checkpoint Blockade Immunotherapy on Atypical/Dysplastic Nevi

StatusRecruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Dec 2025 to May 2029
    • Start date: Nov 1, 2024 to Feb 20, 2025
    v4
  2. Interventions: Nivolumab (Drug), Pembrolizumab (Drug) to Single agent, adjuvant anti-PD1 therapy (Drug)v3 Show 5 more changesShow less
    • Site contact updated
    • Collaborators: 1 to 2
    • Study arms: 2 to 1
    • Eligibility criteria expanded, about 1 word
    • Study description expanded, about 3 words
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Oct 1, 2024 to Nov 1, 2024
    • Site details revised
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
John Kirkwood
4 trials monitored
See all monitored trials
Melanoma
1,092 trials monitored
See 60 trials at risk
This study will examine the impact of anti-programmed cell death 1 (PD1) therapy given in the approved adjuvant therapeutic regimens upon the morphologic, histopathologic, molecular and immunologic as well as genomic features of atypical/dysplastic nevi (A/DN) in patients with a prior documented melanoma of Stages IIB, IIC, IIIA, IIIB, or IIIC and concurrent presence of two or more atypical nevi.
Trial Details
NCT Number NCT06599619
Lead Sponsor John Kirkwood
Collaborators: Melanoma Research Foundation, VeyTel Inc.
Conditions
(from sponsor)		 Melanoma
Related terms Dysplastic Nevus Syndrome, Hereditary Sensory and Autonomic Neuropathies, Melanoma
Enrollment 30 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov